Bruker Corporation vs. Harvard Bioscience Inc
Bruker Corporation (BRKR) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| BRKR | HBIO | |
|---|---|---|
| Market Cap | $8.66 billion | $34.37 million |
| Revenue (TTM) | $3.50 billion | $87.81 million |
| Net Income (TTM) | $-64,500,000 | $-10,412,000 |
BRKR leads on 2 of 3 size & scale factors.
Valuation
| BRKR | HBIO | |
|---|---|---|
| Price / Book | 3.61 | 4.63 |
| Price / Sales | 2.48 | 0.39 |
BRKR and HBIO split the valuation factors evenly.
Profitability
| BRKR | HBIO | |
|---|---|---|
| Net Margin | -1.84% | -11.86% |
| Return on Equity | -2.69% | -140.36% |
BRKR leads on 2 of 2 profitability factors.
Dividend
| BRKR | HBIO | |
|---|---|---|
| Dividend Yield | 0.35% | — |
BRKR and HBIO split the dividend factors evenly.
Risk & Sentiment
| BRKR | HBIO | |
|---|---|---|
| Short Interest | 1.53% | 11.71% |
BRKR leads on 1 of 1 risk & sentiment factors.
Dig deeper: BRKR overview, BRKR financials, HBIO overview, HBIO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.